Mesoblast Revenue and Competitors
Estimated Revenue & Valuation
- Mesoblast's estimated annual revenue is currently $9.7M per year.
- Mesoblast's estimated revenue per employee is $115,952
- Mesoblast's total funding is $412.3M.
Employee Data
- Mesoblast has 84 Employees.
- Mesoblast grew their employee count by -14% last year.
Mesoblast's People
| Name | Title | Email/Phone |
|---|---|---|
1 | COO | Reveal Email/Phone |
2 | VP Clinical Operations | Reveal Email/Phone |
3 | VP, New Technology Development | Reveal Email/Phone |
4 | VP, Head Medical Science Liasons | Reveal Email/Phone |
5 | Head Manufacturing | Reveal Email/Phone |
6 | VP, Engineering Technology | Reveal Email/Phone |
7 | Head Regulatory Affairs and Quality Management | Reveal Email/Phone |
8 | Head Human Resources (Global) | Reveal Email/Phone |
9 | VP, Biometrics | Reveal Email/Phone |
10 | VP, Clinical Operations | Reveal Email/Phone |
Mesoblast Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $35M | 57 | -37% | $122.7M | N/A |
What Is Mesoblast?
Mesoblast; (ASX: MSB; Nasdaq:MESO) is a world leader in innovative cell-based medicines. We have leveraged our proprietary technology platforms based on specialized cells known as mesenchymal lineage adult stem cells (MLCs) to establish what we believe is the most advanced cellular medicines portfolio in the industry. Our ‘off-the-shelf' products are allogeneic - meaning cells from one donor may be used in many different recipients without the need for matching. Our licensee in Japan has launched its MLC-based product for acute graft versus host disease in children and adults in Japan. It is the first allogeneic cell-based product in Japan to be fully approved in Japan. We believe we are well positioned to have the first industrially manufactured allogeneic cell-based product approved in the United States. Our lead product candidates under investigation are: - MPC-150-IM for chronic heart failure - MPC-06-ID for chronic low back pain due to disc degeneration - MSC-100-IV for acute graft versus host disease - MPC-300-IV for biologic refractory rheumatoid arthritis, and diabetic nephropathy We also have a strong emerging pipeline of products for follow-on indications. Led by Chief Executive Silviu Itescu, a pioneer in cellular medicines, the Mesoblast management team has substantial experience in all aspects of biopharmaceutical development. Cell-based therapies, cellular medicines, Mesenchymal Lineage Adult Stem Cells, regenerative medicine
keywords:Biotechnology
$412.3M
Total Funding
84
Number of Employees
$9.7M
Revenue (est)
-14%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Mesoblast News
According to MarketBeat, Mesoblast currently has an average rating of Hold and an average price target of $9.83. Get Mesoblast alerts: Shares...
Silviu Itescu, chief executive of Mesoblast. Please go ahead. Motley Fool Returns. Motley Fool Stock Advisor. Market-beating stocks from our...
As a newly minted board member, Krause did not mince words on the central role he thinks he can play in Mesoblast's path to market. I believe I...
Corporate Governance Council Principles and Recommendations Name of entity Mesoblast Limited ABN/ARBN Financial year ended: 109 431 870 30 June 2021 Our corporate governance statement1 for the period above can be found at:2 ☐ These pages of our annual report: ☒ This URL on our website ...
Management Team Mesoblast has a highly experienced management team made up of individuals who have held senior positions in international pharmaceutical and biotechnology companies. This team is responsible for the strategic direction, operations and success of our company. Silviu Itescu, MBBS ...
Other Companies in Melbourne
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $22.7M | 84 | 42% | N/A |
#2 | $12.2M | 84 | N/A | N/A |
#3 | $17.2M | 84 | 15% | N/A |
#4 | $15.3M | 85 | 21% | N/A |
#5 | $23M | 85 | 5% | N/A |